Experience

EyeBiotech Limited Announces $130 Million Series A

November 14, 2023

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Related contacts

Tom Goodman
Partner, London
Michael Tuscan
Partner, Washington, DC
Christian Plaza
Partner, Reston
Nicola Maguire
Partner, London
Karen Tsai
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Bonnie Weiss McLeod
Of Counsel, Washington, DC
Kerry Corrigan
Associate, London
Ellen Dewhurst
Associate, London

Related Practices & Industries

Cooley Advises Quell Therapeutics on its Exclusive Treg Collaboration With AstraZeneca

June 9, 2023

Cooley advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Frances Stocks Allen
Partner, London
Tom Goodman
Partner, London
Jiqiang Lin
Associate, New York
J. Brian Stalter
Special Counsel, New York
Ellen Dewhurst
Associate, London

Related Practices & Industries

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

David Boles
Partner, London
Claire Keast-Butler
Partner, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Dayne Brown
Associate, New York
Meg Begur
Associate, London
Nicola Squire
Partner, London
Jack Jones
Associate, London
Charlotte Irvine
Associate, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Ivor Elrifi
Partner, New York
Courtney Thorne
Partner, Boston

Related Practices & Industries

Exscientia Inks Investment of up to $525 Million

May 10, 2021

Cooley advised Exscientia, a clinical-stage pharmatech company, on its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion. Lawyers Claire Keast-Butler and Tom Goodman led the Cooley team advising Exscientia.

Read more

Related contacts

Claire Keast-Butler
Partner, London
Tom Goodman
Partner, London
Charlotte Irvine
Associate, London
Paula Holland
Partner, London
Marc Recht
Partner, Boston

Related Practices & Industries

Immunocore – $297 Million IPO

February 5, 2021

Cooley advised Immunocore on its $297.1 million initial public offering of 11,426,280 American depositary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Immunocore, whose securities now trade on the Nasdaq Global Market under the symbol IMCR, is a late-stage biotechnology company pioneering the development of a novel class of T-cell receptor bispecific immunotherapies designed to treat a broad range of diseases. Partners Div Gupta, Eric Blanchard, Nicola Maguire and Claire Keast-Butler led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Eric Blanchard
Partner, New York
Nicola Maguire
Partner, London
Claire Keast-Butler
Partner, London
Courtney Thorne
Partner, Boston
Tom Goodman
Partner, London
Mark Jones
Associate, London
Sam Meiklejohn
Associate, London
Harry Calkin
Associate, London
Dominic Taylor
Associate, London

Related Practices & Industries

View more

Rankings & accolades

The Legal 500 UK: Venture Capital (2022)